CONTENTS
PATENTS: HEALTHCARE
Navigating patent eligibility in digital healthcare
Being useful and novel may not be enough, warn Linda Thayer, Aaron Capron and Sneha Nyshadham of Finnegan, Henderson, Farabow, Garrett & Dunner.
ANTIBODIES
The uncertain future of antibody claims
Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
PATENTS: NON-OBVIOUSNESS
When the inventor is artificial
Will the same tests for non-obviousness be applied to pharma inventions developed using AI, asks MaryAnne Armstrong of Birch Stewart Kolasch Birch.
CHINA: PATENTS
The curious case of Wuhan’s Institute of Virology and remdesivir
Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.
EPO: EXAMINATION GUIDELINES
EPO’s new examination guidelines
The updated rules include important changes involving amino or nucleic acid sequences and antibodies, Clare Roskell and Samantha Moodie of Mathys & Squire explain.
RUSSIA: NOVELTY
A point of principle
Is the ‘narrower–broader’ principle a general rule or the exception when evaluating the novelty criterion of patentability, asks Elena Nazina of Gorodissky & Partners.
PATENT VALIDATION
Have patent, will travel
Deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
PATENT FILING
The startup scene
Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.
SOVEREIGN IMMUNITY
Sovereign immunity: a venue-dependent protection
A University of Texas dispute perfectly illustrates the differing role sovereign immunity takes in proceedings at the PTAB and district court, say Simon Roberts, Nitya Anand and Eric Wang of Hogan Lovells.
SECOND MEDICAL USE
A regulatory perspective
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
CANADA: MEDICINE PRICING
Pricing, patents and the PMPRB
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator.
